- Home
- NITO vs BTAI Comparison
NITO vs BTAI Comparison
Compare NITO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- BTAI
- Stock Information
- Founded
- NITO 2009
- BTAI 2017
- Country
- NITO Israel
- BTAI United States
- Employees
- NITO 5
- BTAI N/A
- Industry
- NITO
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- NITO
- BTAI Health Care
- Exchange
- NITO NYSE
- BTAI Nasdaq
- Market Cap
- NITO 6.6M
- BTAI 8.3M
- IPO Year
- NITO N/A
- BTAI 2018
- Fundamental
- Price
- NITO $0.25
- BTAI $1.93
- Analyst Decision
- NITO
- BTAI Buy
- Analyst Count
- NITO 0
- BTAI 5
- Target Price
- NITO N/A
- BTAI $34.60
- AVG Volume (30 Days)
- NITO 1.2M
- BTAI 286.0K
- Earning Date
- NITO 08-13-2025
- BTAI 08-05-2025
- Dividend Yield
- NITO N/A
- BTAI N/A
- EPS Growth
- NITO N/A
- BTAI N/A
- EPS
- NITO N/A
- BTAI N/A
- Revenue
- NITO $232,000.00
- BTAI $1,852,000.00
- Revenue This Year
- NITO N/A
- BTAI $5.03
- Revenue Next Year
- NITO N/A
- BTAI $291.01
- P/E Ratio
- NITO N/A
- BTAI N/A
- Revenue Growth
- NITO 24.74
- BTAI 5.47
- 52 Week Low
- NITO $0.16
- BTAI $1.17
- 52 Week High
- NITO $3.49
- BTAI $21.92
- Technical
- Relative Strength Index (RSI)
- NITO 47.13
- BTAI 56.97
- Support Level
- NITO $0.22
- BTAI $1.69
- Resistance Level
- NITO $0.26
- BTAI $2.08
- Average True Range (ATR)
- NITO 0.02
- BTAI 0.20
- MACD
- NITO 0.00
- BTAI 0.02
- Stochastic Oscillator
- NITO 41.98
- BTAI 61.84
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork. The Company has two reportable segments: Pathogen prevention and prolong shelf life, and the N2O emissions Global warming solutions.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.